Teysuno 欧州連合 - スペイン語 - EMA (European Medicines Agency)

teysuno

nordic group b.v. - tegafur, gimeracil, oteracil - neoplasmas estomacales - agentes antineoplásicos - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

테푸로실캅셀(수출명:UCFT,USFT,UTECIL) 大韓民国 - 韓国語 - MFDS (식품 의약품 안전부)

테푸로실캅셀(수출명:ucft,usft,utecil)

baskhanbiopharma inc - uracil/tegafur - 백색의 분말이 충진된 상.하 백색의 캅셀제이다 - 1캡슐 중 406밀리그램 - 첨가제 : (상ㆍ하)백색경질캡슐, 포비돈 - [421]항악성종양제 - 다음 질환의 자각적, 타각적 증상의 완화 : 두경부암, 위암, 결장ㆍ직장암, 간암, 담낭ㆍ담관암, 췌장암, 폐암, 유방암, 방광암, 전립선암, 자궁경부암

優富多膠囊 台湾 - 中国語 - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

優富多膠囊

台灣大塚製藥股份有限公司 台北市中山區復興北路378號11樓 (14001297) - tegafur (ftorafur);;uracil - 膠囊劑 - 主成分 () ; tegafur (ftorafur) (1008400300) mg; uracil (9600098800) mg - tegafur, combinations - 胃癌、結腸癌、大腸癌、乳癌、與cisplatin併用治療轉移及末期肺癌、頭頸部癌、用於病理分期t2之第一期b肺腺癌病人手術後輔助治療。

Teysuno 欧州連合 - フランス語 - EMA (European Medicines Agency)

teysuno

nordic group b.v. - tegafur, gimeracil, l'otéracil - néoplasmes stomacaux - agents antinéoplasiques - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Teysuno 欧州連合 - 英語 - EMA (European Medicines Agency)

teysuno

nordic group b.v. - tegafur, gimeracil, oteracil - stomach neoplasms - antineoplastic agents - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5.1).- as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Teysuno 20mg5.8mg15.8mg capsules イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

teysuno 20mg5.8mg15.8mg capsules

nordic pharma ltd - tegafur; gimeracil; oteracil potassium - capsule - 20mg ; 5.8mg ; 15.8mg

Teysuno 15mg4.35mg11.8mg capsules イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

teysuno 15mg4.35mg11.8mg capsules

nordic pharma ltd - tegafur; gimeracil; oteracil potassium - capsule - 15mg ; 4.35mg ; 11.8mg

TEYSUNO (15+4,35+11,8)MG/CAP ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ ギリシャ - ギリシャ語 - Εθνικός Οργανισμός Φαρμάκων

teysuno (15+4,35+11,8)mg/cap καψακιο, σκληρο

nordic group b.v., netherlands - tegafur, gimeracil, oteracil - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - (15+4,35+11,8)mg/cap - 0017902237 - tegafur - 15.000000 mg; 0103766252 - gimeracil - 4.350000 mg; 002207752 - oteracil - 11.800000 mg - tegafur, combinations

TEYSUNO (20+5,8+15,8)MG/CAP ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ ギリシャ - ギリシャ語 - Εθνικός Οργανισμός Φαρμάκων

teysuno (20+5,8+15,8)mg/cap καψακιο, σκληρο

nordic group b.v., netherlands - tegafur, gimeracil, oteracil - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - (20+5,8+15,8)mg/cap - 0017902237 - tegafur - 20.000000 mg; 0103766252 - gimeracil - 5.800000 mg; 002207752 - oteracil - 15.800000 mg - tegafur, combinations